$4.16
0.37[9.76%]
At close: Apr 29
$4.16
0[0.00%]
After Hours: 4:00PM EDT
Geron
(NASDAQ:GERN)Latest News for Geron Stock (NASDAQ:GERN)
Geron Stock (NASDAQ: GERN)
Categories: All
Monday, April 29, 2024
- Geron Corporation shares are trading higher after TD Cowen initiated coverage on the stock with a Buy rating and a $10 price target.Benzinga Newsdesk - 5 hours ago
- Navigating 10 Analyst Ratings For GeronBenzinga Insights - 7 hours ago
- TD Cowen Initiates Coverage On Geron with Buy Rating, Announces Price Target of $10Benzinga Newsdesk - 10 hours ago
Friday, April 26, 2024
Friday, April 12, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
Tuesday, March 19, 2024
Monday, March 18, 2024
- STAT News' Adam Feuerstein Publishes "I Was Wrong About Geron's Blood Cancer Drug. Now, Is It A Takeover Target?"; Shares See VolumeHappy Mohamed - Mar 18, 2024, 9:08AM
- Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 18, 2024, 8:06AM
- Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market SessionAvi Kapoor - Mar 18, 2024, 5:57AM
Friday, March 15, 2024
- Inflation Squeezes Stocks, Bitcoin Slips To $68,000, While Commodities On Track For Best Week In Months: What's Driving Markets Friday?Piero Cingari - Mar 15, 2024, 2:12PM
- Needham Maintains Buy on Geron, Raises Price Target to $5Benzinga Newsdesk - Mar 15, 2024, 1:03PM
- What's Going On With Cancer Focused-Geron Stock On Friday?Vandana Singh - Mar 15, 2024, 11:29AM
- Goldman Sachs Maintains Buy on Geron, Raises Price Target to $5Benzinga Newsdesk - Mar 15, 2024, 10:44AM
- Wedbush Reiterates Outperform on Geron, Maintains $6 Price TargetBenzinga Newsdesk - Mar 15, 2024, 9:41AM
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga Insights - Mar 15, 2024, 9:06AM
- Geron shares are trading lower. The company announced that the FDA Oncologic Drugs Advisory Committee voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.Benzinga Newsdesk - Mar 15, 2024, 7:54AM
Thursday, March 14, 2024
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Mar 14, 2024, 5:33PM
- Geron Stock Is Soaring After Hours: What's Going On?Adam Eckert - Mar 14, 2024, 5:03PM
- Geron shares are trading higher after the company announced that the FDA Oncologic Drugs Advisory Committee voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.Benzinga Newsdesk - Mar 14, 2024, 4:28PM
- Geron Shares Resume TradeBenzinga Newsdesk - Mar 14, 2024, 4:25PM
- Trading Halt: Halt status updated at 4:20:00 PM ET: Quotation Resumption: News and Resumption TimesBenzinga Newsdesk - Mar 14, 2024, 4:20PM
- Geron Announces FDA Oncologic Drugs Advisory Committee Votes In Favor Of The Clinical Benefit/Risk Profile Of Imetelstat For The Treatment Of Transfusion-Dependent Anemia In Patients With Lower-Risk MDSBenzinga Newsdesk - Mar 14, 2024, 3:57PM
- FDA Advisers Vote 12-To-2 In Favor Of Benefits Of Geron's Blood Disorder Drug Outweighing Its Risks Based On Late-Stage Trial DataBenzinga Newsdesk - Mar 14, 2024, 3:17PM
- Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News PendingBenzinga Newsdesk - Mar 14, 2024, 6:55AM
Wednesday, March 13, 2024
Tuesday, March 12, 2024
- Why Geron Stock Is Falling TodayErica Kollmann - Mar 12, 2024, 2:43PM
- FDA Casts Doubts On Geron's Blood Cancer Drug, But Analyst Sees High Probability For Imetelstat's Potential Approval For MDS Anemia TreatmentVandana Singh - Mar 12, 2024, 2:20PM
- Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Mar 12, 2024, 2:07PM
- Geron shares are trading lower after FDA staff reviewers reportedly said treatment with the company's anemia drug Imetelstat is associated with risks that might be considered substantial.Benzinga Newsdesk - Mar 12, 2024, 12:12PM
- FDA Staff Reviewers Say Treatment With Geron's Anemia Drug Imetelstat Is Associated With Risks That Might Be Considered Substantial; It Is Not Clear That Risks Of Treatment With Imetelstat Are Outweighed By The Potential Benefit For The Intended Population; The Patient-Reported Outcomes Are Not Supportive Of Geron's Treatment EffectBenzinga Newsdesk - Mar 12, 2024, 9:38AM
- Needham Reiterates Buy on Geron, Maintains $4 Price TargetBenzinga Newsdesk - Mar 12, 2024, 5:58AM
Monday, March 04, 2024
Wednesday, February 28, 2024
- Needham Reiterates Buy on Geron, Maintains $4 Price TargetBenzinga Newsdesk - Feb 28, 2024, 11:46AM
- Geron Q4 EPS $(0.09) Beats $(0.10) Estimate, Sales $23.00K Miss $70.00K Estimate; $378.1M In Cash, Cash Equivalents, And Marketable Securities Projected To Fund Operating Expenses Into The Third Quarter Of 2025Benzinga Newsdesk - Feb 28, 2024, 7:08AM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM
Tuesday, January 30, 2024
Wednesday, December 06, 2023
Wednesday, November 29, 2023
Thursday, November 02, 2023
- Geron IMerge Phase 3 Presentations At Upcoming ASH Annual Meeting Reinforce Significant Durability And Breadth Of Effect Of Imetelstat In Lower Risk MDSBenzinga Newsdesk - Nov 2, 2023, 9:17AM
- Geron's As Of September 30, 2023, Had $381.9M In Cash, Cash Equivalents, And Marketable Securities Expected To Be Sufficient To Fund Its Projected Operating Requirements Through The End Of Q3 2025Benzinga Newsdesk - Nov 2, 2023, 8:03AM
- Geron Q3 EPS $(0.08) Beats $(0.10) Estimate, Sales $164.00K Beat $59.00K EstimateBenzinga Newsdesk - Nov 2, 2023, 8:01AM
- Earnings Scheduled For November 2, 2023Benzinga Insights - Nov 2, 2023, 4:56AM